These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35642433)

  • 21. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
    Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
    Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ASO Author Reflections: Immune-Related Adverse Events During Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer May Influence Time to Adjuvant Radiation.
    Myers SP; Downs-Canner SM
    Ann Surg Oncol; 2024 Aug; 31(8):5205-5206. PubMed ID: 38776008
    [No Abstract]   [Full Text] [Related]  

  • 23. Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
    Philipovskiy A; Chambers K; Konstantinidis I; McCallum R; Corral J; Gaur S
    Immunotherapy; 2020 Dec; 12(18):1293-1302. PubMed ID: 32988260
    [No Abstract]   [Full Text] [Related]  

  • 24. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
    Kyte JA; Røssevold A; Falk RS; Naume B
    J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Not Available].
    Gonçalves A
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S76-89. PubMed ID: 27494978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.
    van Dongen MGJ; Kok M
    Ann Oncol; 2020 May; 31(5):556-557. PubMed ID: 32171753
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
    Gianni L; Huang CS; Egle D; Bermejo B; Zamagni C; Thill M; Anton A; Zambelli S; Bianchini G; Russo S; Ciruelos EM; Greil R; Semiglazov V; Colleoni M; Kelly C; Mariani G; Del Mastro L; Maffeis I; Valagussa P; Viale G
    Ann Oncol; 2022 May; 33(5):534-543. PubMed ID: 35182721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
    Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
    Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. State of art of advanced triple negative breast cancer.
    Khosravi-Shahi P; Cabezón-Gutiérrez L; Aparicio Salcedo MI
    Breast J; 2019 Sep; 25(5):967-970. PubMed ID: 31155832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
    Kang C; Syed YY
    Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.
    Otani Y; Mori K; Morikawa N; Mizutani M; Yasojima H; Masuyama M; Mano M; Masuda N
    Immunotherapy; 2021 Feb; 13(3):189-194. PubMed ID: 33225795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab in Early Triple-Negative Breast Cancer.
    Ganguly S; Gogia A
    N Engl J Med; 2022 May; 386(18):1771. PubMed ID: 35507497
    [No Abstract]   [Full Text] [Related]  

  • 35. Pembrolizumab in Early Triple-Negative Breast Cancer. Reply.
    Schmid P; Cortes J; Dent R
    N Engl J Med; 2022 May; 386(18):1771-1772. PubMed ID: 35507498
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer.
    Shah M; Osgood CL; Amatya AK; Fiero MH; Pierce WF; Nair A; Herz J; Robertson KJ; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    Clin Cancer Res; 2022 Dec; 28(24):5249-5253. PubMed ID: 35925043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atezolizumab for the treatment of breast cancer.
    Reddy SM; Carroll E; Nanda R
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.